| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 16th October 2020 | David Sidransky | 16,667 | Exercise of derivative | $5.46 | $91,001.82 |
| 16th October 2020 | David Sidransky | 10,100 | Payment by withholding | $9.01 | $91,001.00 |
| 20th May 2020 | David Sidransky | 10 | Open or private purchase | $6.98 | $69.80 |
| 13th May 2020 | David Sidransky | 70 | Open or private purchase | $5.96 | $417.20 |
| 12th May 2020 | David Sidransky | 90 | Open or private purchase | $5.90 | $531.00 |
| 7th May 2020 | David Sidransky | 10 | Open or private purchase | $5.42 | $54.20 |
| 11th June 2018 | Yaron Adler | 37,662 | Conversion of derivative | $0.00 |
Orgenesis
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Orgenesis, Inc. engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company was founded on June 5, 2008 by Sarah Ferber and is headquartered in Germantown, MD.
Ticker: ORGS
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1460602
Employees: 309
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Revenue From Related Parties of $279 Th for the period Apr 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $772 Th for the period Jan 2020 to Jun 2020 in the context of all up
Revenue From Related Parties of $556 Th for the period Apr 2019 to Jun 2019 in the context of all up
Revenue From Related Parties of $556 Th for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $97 M (91009%)
Inventory, Net: $176 Th (29%)
Assets, Current: $104 M (33%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $802 Th (2191%)
Assets: $119 M (28%)
Accounts Payable, Current: $2 M (-70%)
Liabilities, Current: $20 M (-53%)
Other Liabilities, Noncurrent: $284 Th (-14%)
Liabilities: $31 M (-44%)
Common Stock, Value, Issued: $2 Th (0%)
Common Stock, Shares, Issued: $22 M (36%)
Additional Paid in Capital, Common Stock: $123 M (29%)
Retained Earnings (Accumulated Deficit): $34 M (-61%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $10 Th (-95%)
Stockholders' Equity (Parent): $88 M (1510%)
Liabilities and Equity: $119 M (28%)
Revenue: $1 M (-48%)
Research and Development: $25 M (-15%)
Operating Income/Loss: $27 M (-20%)
Provision for income taxes: $12 Th (-65%)
EPS (basic): $0.95 (0%)
EPS (diluted): $0.95 (0%)
